Systematic review / meta-analysis / 2014
Higher circulating vitamin D levels at or near cancer diagnosis were linked to better survival outcomes.
A meta-analysis of 25 studies involving 17,332 cancer cases assessed associations between circulating 25(OH)D levels at or near diagnosis and patient outcomes. Comparing the highest to lowest quartiles, pooled hazard ratios for overall survival were 0.55 (95% CI = 0.33-0.91) for colorectal cancer, 0.63 (95% CI = 0.51-0.77) for breast cancer, and 0.48 (95% CI = 0.36-0.64) for lymphoma. Higher 25(OH)D levels were also significantly associated with reduced cancer-specific mortality for colorectal cancer (P = .005) and lymphoma (P < .001), as well as improved disease-free survival for breast cancer (P < .001) or lymphoma (P < .05). A 10-nmol/L increment in circulating 25(OH)D was associated with a hazard ratio of 0.96 (95% CI = 0.95-0.97) for overall survival.
Shows an association, not proof of cause and effect.
- Study type
- Systematic review and meta-analysis
- Who was studied
- 25 studies with 17,332 cancer cases
- What was measured
- Overall survival, cancer-specific mortality, and disease-free survival
THE PAPER
Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis.
Li M, Chen P, Li J, Chu R, Xie D, Wang H. J Clin Endocrinol Metab, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.